Protective effect of bezafibrate on streptozotocin-induced oxidative stress and toxicity in rats

Toxicology

Volumn 229, Issue 1-2, 2007, Pages 165-172

  Anwer, Tarique ^a   Sharma, Manju ^a   Pillai, K K ^a   Haque, S E ^a   Alam, M M ^a   Zaman, M S ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Bezafibrate; Diabetes mellitus; Lipid peroxidation; Oxidative stress; Streptozotocin

Indexed keywords

ANTIOXIDANT; BEZAFIBRATE; CATALASE; GLUCOSE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; STREPTOZOCIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; LIPID PEROXIDATION; LIVER; MALE; NONHUMAN; OXIDATIVE STRESS; PANCREAS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ANIMALS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; BEZAFIBRATE; BLOOD GLUCOSE; CATALASE; DIABETES MELLITUS, EXPERIMENTAL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HYPERGLYCEMIA; INJECTIONS, INTRAPERITONEAL; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; LIPID PEROXIDATION; LIVER; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; RATS; RATS, WISTAR; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TIME FACTORS;

ANIMALIA;

EID: 33845305011     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2006.10.016     Document Type: Article

References (45)

1. Alvarez J.F., Barbera A., Nadal B., Barcelo-Batllori S., Piquer S., Claret M., Guinovart J.J., Guinovart, and Gomis R. Stable and functional regeneration of pancreatic beta-cell population in n-STZ rats treated with tungstate. Diabetologia 47 (2004) 470-477
2. Avogaro A., Beltramello P., and Marin R. Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients. Atherosclerosis 113 1 (1995) 117-124
3. Baynes J.W. Role of oxidative stress in the development of complications in diabetes. Diabetes 40 (1991) 405-412
4. Baynes J.W., and Thorpe S.R. The role of oxidative stress in diabetic complications. Curr. Opin. Endocrinol. 3 (1997) 277-284
5. Braham D., and Trinder. An improved colour reaction for the determination of blood glucose by oxidase system. Analyst (1972) 142-144
6. Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome prolifirator-activated receptor (PPARs): tissue distribution of PPAR-alpha, -beta, and gamma in the adult rat. Endocrinology 137 (1996) 354-366
7. Chugh S.N., Kakkar R., Kalra S., and Sharma A. An evaluation of oxidative stress in diabetes mellitus during uncontrolled and controlled state and after vitamin E supplementation. J. Assoc. Phys. Ind. 47 (1999) 380-383
8. Claiborne A. Catalase activity. In: Greenwald R.A. (Ed). CRC Handbook of Methods for Oxygen Radical Research (1985), CRC Press, Boca Raton, FL 283-284
9. Dongmei J., and Makoto O. Bezafibrate, a peroxisome proliferator-activated receptor (PPAR-α) activator, prevents pancreatic degeneration in obese and diabetic rats. Pancreas 24 3 (2003) 286-291
10. Foxworthy P.S., and Eacho P.I. Conditions influencing the induction of peroxisomal b-oxidation in cultured rat hepatocytes. Toxicol. Lett. 30 (1986) 189-196
11. Foxworthy P.S., White S.L., Hoover D.M., and Eacho P.I. Effect of ciprofibrate, bezafibrate, and LY171883 on peroxisomal b-oxidation in cultured rat, dog, and rhesus monkey hepatocytes. Toxicol. Appl. Pharmacol. 104 (1990) 386-394
12. Goa K.L., Barradell L.B., and Plosker G.L. Bezafibrate: an update of its pharmacology and use in the management of dyslipidemia. Drugs 52 (1996) 725-753
13. Groop L.C. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes. Metab. 1 Suppl 1 (1991) S1-S7
14. Hauggard N. Cellular mechanism of oxygen toxicity. Physiol. Rev. 48 (1968) 311-373
15. Hideo M., Kenji O., Kei K., Michitaka H., Yukio T., and Takayuki I. Improved insulin sensitivity by bezafibrate in rats. Diabetes 46 (1997) 348-353
16. Higuchi Y. Lipid peroxides and alpha-tocopherol in rat streptozotocin induced diabetes mellitus. Acta. Med. Okayama. 36 (1982) 165-175
17. Hiramatsu K., and Arimori S. Increased superoxide production by mononuclear cells of patients with hypertriglyceridemia and diabetes. Diabetes 37 (1988) 832-837
18. 2+-superoxide dismutase in the liver. Life Sci. 63 2 (1998) 135-144
19. Iwasaki S., Tsuda K., and Ueta H. Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol. Res. 16 (1999) 12-18
20. Kakkar R., Kalra J., Manth S.V., and Parsad K. Lipid peroxidation and activity of antioxidant enzymes in diabetic rats. Mol. Cell. Biochem. 151 (1995) 113-119
21. Kalendra B., Oztruk M., Tuncdemir M., Usyal O., Dagistanli F.K., Yagenaga I., and Erek E. Renoprotective effect of valsartan and enalapril in STZ-induced diabetes in rats. Acta Histochem. 104 (2002) 123-130
22. Kim M.J., Ryu G.R., Chung J.S., Sim S.S., Min Dos Rhie D.J., Yoon S.H., Hahn S.J., Kim M.S., and Jo Y.M. Protective effect of epicatechin against the toxic effects of STZ on rat pancreatic islets: in vivo and in vitro. Pancreas 26 (2003) 292-299
23. Konukoglu D., Serin O., Kemerli D.G., Serin E., Hayiroglu A., and Oner B. A study on the carotid artery intima-media thickness and its association with lipid peroxidation. Clin. Chim. Acta 277 (1998) 91-98
24. Kurihara T., Furukawa M., and Tsuchiya M. Effect of bezafibrate in the treatment of primary biliary cirrhosis. Curr. Ther. Res. Clin. Exp. 61 (2000) 74-82
25. Lowry O.H., Rosenbrough N.J., Forr A.L., and Randall R.J. Protein measurements with the Folin's reagent. J. Biol. Chem. 913 (1951) 265-275
26. Maritim A.C., Sanders R.A., and Watkins J.B. Effects of α-lipoic acid on biomarkers of oxidative stress in streptozotocin-induced diabetic rats. J. Nutr. Biochem. 14 (2003) 288-294
27. Marklund S., and Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur. J. Biochem. 47 (1974) 469-474
28. Marx N., Duez H., Fruchart J.C., and Stael B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94 (2004) 1168-1178
29. Mohandas J., Marshall J.J., Duggin G.G., Horvath J.S., and Tiller D.J. Low activities of glutathione-related enzymes as factors in the genesis of urinary bladder cancer. Cancer Res. 44 (1984) 5086-5091
30. Nishigaki J., Hagihara M., Tsunekawa H., Maseki M., and Yagi K. Lipid peroxide levels of serum lipoprotein fraction of diabetic proteins. Biochem. Med. 25 (1981) 373-378
31. Ogawa S., Takeuchi K., Sugimura K., Fukuda M., Lee R., Ito S., and Sato T. Bezafibrate reduced blood glucose in type 2 diabetes mellitus. Metabolism 49 (2000) 331-333
32. Ohkawa H., Ohishi N., and Yagi K. Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95 (1979) 351-358
33. Pineda, Torra, Gervois P., and Steals B. Peroxisome proliferator-activated receptor α (PPAR-α) in metabolic disease, inflammation, atherosclerosis and aging. Curr. Opin. Lipidol. 10 (1999) 151-159
34. Porta Jr. D., and Kahn S.E. β-Cell dysfunction and failure in type 2 diabetes: potential mechanism. Diabetes 50 Suppl. 1 (2001) S160-S163
35. Riccardi G., Genovese S., and Saladilamacchia G. Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with or without diabetes. Atherosclerosis 75 (1989) 175-181
36. Saharia P., Margolis S., Zuidema G.D., and Cameron J.L. Acute pancreatitis with hyperlipidemia studies with an isolated perfused canine pancreas. Surgery 82 1 (1977) 60-67
37. Sedlak J., and Lindsay R.H. Estimation of total, protein bound and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal. Biochem. 25 (1968) 192-205
38. Sharma R., Lake B.G., and Gibson G.G. Co-induction of microsomal cytochrome P-452 and the peroxisomal fatty acid b-oxidation pathway in the rat by clofibrate and di-(2-ethylhexyl)phthalate. Biochem. Pharmacol. 37 (1988) 1203-1206
39. Stefek M., Tribulova N., Gajdoski A., and Gajdosikova A. The pyridoindole antioxidant stobadine attenuates histochemical changes in kidney of STZ-induced diabetic rats. Acta Histochem. 104 (2002) 413-417
40. Stewart M.W., Dyer R.G., Alberti K.G., and Laker M.F. The effect of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidemia. Diabetes Med. 12 3 (1995) 250-257
41. Szkudelski T. The mechanism of alloxan and streptozotocin action in β-cells of the rat pancreas. Physiol. Res. 50 (2001) 537-546
42. Uchida T., Tsuchiya R., Harada N., Tsunoda T., Yamaguchi T., Eto T., and Furukawa M. Ischemic changes in the pancreas of Watanabe Heritable Hyper-Lipidemic (WHHL) rabbits. Int. J. Pancreatol. 3 4 (1988) 261-271
43. Williams A.J., and Baker F.E. The effect of bezafibrate on hyperlipidemia in experimental nephrotic syndrome in rats. J. Pharm. Pharmacol. 37 (1985) 741-743
44. Wolff S.P., Jang Z.Y., and Hunt V.J. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free. Radic. Biol. Med. 10 (1991) 339-352
45. Yamagishi N., Nakayama K., Wakatsuki T., and Hatayama T. Characteristic changes of stress protein expression in streptozotocin induced diabetic rats. Life Sci. 9 (2001) 2603-2609